Mass spectrometric methods for evaluation of voriconazole avian pharmacokinetics and the inhibition of its cytochrome P450-induced metabolism

References

• Andes D, Pascual A, Marchetti O. 2008. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 53(1):24–34. doi:10.1128/AAC.00705-08.
   PubMed Web of Science ®Google Scholar
• Ashenhurst J. 2023. Ortho-, para- and meta- directors in electrophilic aromatic substitution. Available at https://www.masterorganicchemistry.com/2018/01/29/ortho-para-and-meta-directors-in-electrophilic-aromatic-substitution/, accessed August 24, 2023.
   Google Scholar
• Bachmann F, Meyer Zu Schwabedissen HE, Duthaler U, Krähenbühl S. 2022. Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine. Br J Clin Pharmacol. 88(4):1885–1896. doi:10.1111/bcp.15108.
   PubMed Web of Science ®Google Scholar
• Backman JT, Schröder MT, Neuvonen PJ. 2008. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol. 64(1):17–24. doi:10.1007/s00228-007-0389-y.
   PubMed Web of Science ®Google Scholar
• Barbarino JM, Owusu OA, Klein TE, Altman RB. 2017. PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics. 27(5):201–209. doi:10.1097/FPC.0000000000000276.
   PubMed Web of Science ®Google Scholar
• Beernaert LA, Pasmans F, Van Waeyenberghe L, Haesebrouck F, Martel A. 2010. Aspergillus infections in birds: a review. Avian Pathol. 39(5):325–331. doi:10.1080/03079457.2010.506210.
   PubMed Web of Science ®Google Scholar
• Blum RA, D’Andrea DT, Florentino BM, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Goldstein H, Schentag JJ. 1991. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 114(9):755–757. doi:10.7326/0003-4819-114-9-755.
   PubMed Web of Science ®Google Scholar
• Bolhuis MS, Panday PN, Pranger AD, Kosterink JGW, Alffenaar J-WC. 2011. Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams. Pharmaceutics. 3(4):865–913. doi:10.3390/pharmaceutics3040865.
   PubMedGoogle Scholar
• Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, Burger DM, Saravolatz LD. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 48(10):1441–1458. doi:10.1086/598327.
   PubMed Web of Science ®Google Scholar
• Cadranel J, Philippe B, Hennequin C, Bergeron A, Bergot E, Bourdin A, Cottin V, Jeanfaivre T, Godet C, Pineau M, et al. 2012. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis. 31(11):3231–3239. doi:10.1007/s10096-012-1690-y.
   PubMed Web of Science ®Google Scholar
• Dagenais TR, Keller NP. 2009. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev. 22(3):447–465. doi:10.1128/CMR.00055-08.
   PubMed Web of Science ®Google Scholar
• Davis JL, Salmon JH, Papich MG. 2006. Pharmacokinetics of voriconazole after oral and intravenous administration to horses. Am J Vet Res. 67(6):1070–1075. doi:10.2460/ajvr.67.6.1070.
   PubMed Web of Science ®Google Scholar
• Deodhar M, Rihani SBA, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V. 2020. Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics. 12(9):846. doi:10.3390/pharmaceutics12090846.
   PubMed Web of Science ®Google Scholar
• Egle H, Trittler R, König A, Kümmerer K. 2005. Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique. J Chromatogr B Analyt Technol Biomed Life Sci. 814(2):361–367. doi:10.1016/j.jchromb.2004.10.069.
   PubMed Web of Science ®Google Scholar
• Farouk F, Khalil RM, Abdelbary A, El Arini SK, Basha M, El-Hashemy HA. 2021. Bioanalytical comparison of transdermal delivery of tizanidine from different nanovesicular carriers. J Pharm Innov. 16(2):384–390. doi:10.1007/s12247-020-09447-z.
   Web of Science ®Google Scholar
• FDA. 2011. CIPRO® (ciprofloxacin hydrochloride). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.pdf. Accessed August 24, 2023.
   Google Scholar
• FDA. 2023. Drug Development and Drug Interactions. Available at https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers., Accessed August 24, 2023.
   Google Scholar
• Fischer D, Van Waeyenberghe L, Failing K, Martel A, Lierz M. 2018. Single tracheal inoculation of Aspergillus fumigatus conidia induced aspergillosis in juvenile falcons (Falco spp.). Avian Pathol. 47(1):33–46. doi:10.1080/03079457.2017.1360470.
   PubMed Web of Science ®Google Scholar
• Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. 2004. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther. 76(6):598–606. doi:10.1016/j.clpt.2004.08.018.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 2022. Inhibition of cytochrome P450 enzymes by drugs - molecular basis and practical applications. Biomol Ther (Seoul). 30(1):1–18. doi:10.4062/biomolther.2021.102.
   PubMed Web of Science ®Google Scholar
• Guzman DS-M, Flammer K, Papich MG, Grooters AM, Shaw S, Applegate J, Tully TN. 2010. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan parrots (Amazona ventralis). Am J Vet Res. 71(4):460–467. doi:10.2460/ajvr.71.4.460.
   PubMed Web of Science ®Google Scholar
• Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. 2020. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol. 94(11):3671–3722. doi:10.1007/s00204-020-02936-7.
   PubMed Web of Science ®Google Scholar
• Hamadeh IS, Klinker KP, Borgert SJ, Richards AI, Li W, Mangal N, Hiemenz JW, Schmidt S, Langaee TY, Peloquin CA, et al. 2017. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenet Genomics. 27(5):190–196. doi:10.1097/FPC.0000000000000277.
   PubMed Web of Science ®Google Scholar
• Henry H, Sobhi HR, Scheibner O, Bromirski M, Nimkar SB, Rochat B. 2012. Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun Mass Spectrom. 26(5):499–509. doi:10.1002/rcm.6121.
   PubMed Web of Science ®Google Scholar
• Ince I, Knibbe CA, Danhof M, de Wildt SN. 2013. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet. 52(5):333–345. doi:10.1007/s40262-013-0041-1.
   PubMed Web of Science ®Google Scholar
• Jenkins N, Black M, Schneider HG. 2018. Simultaneous determination of voriconazole, posaconazole, itraconazole and hydroxy-itraconazole in human plasma using LCMS/MS. Clin Biochem. 53:110–115. doi:10.1016/j.clinbiochem.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Jeong S, Nguyen PD, Desta Z. 2009. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 53(2):541–551. doi:10.1128/AAC.01123-08.
   PubMed Web of Science ®Google Scholar
• Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. 2003. Voriconazole. Clin Ther. 25(5):1321–1381. doi:10.1016/s0149-2918(03)80126-1.
   PubMed Web of Science ®Google Scholar
• Johnson SD, Buchweitz JP, Lehner AF. 2022. Single oral or intravenous administration of voriconazole achieved recommended therapeutic minimum inhibitory concentrations against Aspergillus in the common raven (Corvus corax). Am J Vet Res. 83(10):1–8. doi:10.2460/ajvr.22.03.0055.
   Google Scholar
• Kwon YJ, Shin S, Chun YJ. 2021. Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes. Arch Pharm Res. 44(1):63–83. doi:10.1007/s12272-021-01306-w.
   PubMed Web of Science ®Google Scholar
• Lehner AF, Dirikolu L, Johnson M, Buchweitz JP, Langlois DK. 2020. Liquid chromatography/tandem mass spectrometric analysis of penicillamine for its pharmacokinetic evaluation in dogs. Toxicol Mech Methods. 30(9):687–702. doi:10.1080/15376516.2020.1814467.
   PubMed Web of Science ®Google Scholar
• Li YS, Jiang ML, Thunders M, Ai XJ, Qiu JP. 2018. Effect of enrofloxacin and roxarsone on CYP450s in pig. Res Vet Sci. 117:97–98. doi:10.1016/j.rvsc.2017.11.014.
   PubMed Web of Science ®Google Scholar
• Lofgren LA, Lorch JM, Cramer RA, Blehert DS, Berlowski-Zier BM, Winzeler ME, Gutierrez-Perez C, Kordana NE, Stajich JE. 2022. Avian-associated Aspergillus fumigatus displays broad phylogenetic distribution, no evidence for host specificity, and multiple genotypes within epizootic events. G3 (Bethesda). 12(5):jkac075. doi:10.1093/g3journal/jkac075.
   PubMedGoogle Scholar
• Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, Husain S. 2016. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 71(7):1786–1799. doi:10.1093/jac/dkw099.
   PubMed Web of Science ®Google Scholar
• Mangal N, Hamadeh IS, Arwood MJ, Cavallari LH, Samant TS, Klinker KP, Bulitta J, Schmidt S. 2018. Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults. Clin Pharmacol Ther. 104(5):957–965. doi:10.1002/cpt.1012.
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez S, Rosado-de-Christenson ML, Carter BW. 2017. Invasive aspergillosis. In Specialty imaging: HRCT of the lung (Second Edition). New York: Elsevier, p. 160–163. doi:10.1016/B978-0-323-52477-3.50059-7.
   Google Scholar
• Merry C, Flexner CW. 2012. Chapter 13 - Pharmacology of antiretroviral drugs. In: Volberding PA, Greene WC, Lange JMA, Gallant JE, Sewankambo N, editors. Sande’s HIV/AIDS Medicine . New York: Elsevier, Inc.; p. 169–176. doi:10.1016/B978-1-4557-0695-2.00013-4.
   Google Scholar
• Meyler’s Side Effects of Drugs (Sixteenth Edition). 2016. The international encyclopedia of adverse drug reactions and interactions. New York: Elsevier, Inc.; p. 504–521.
   Google Scholar
• Mikus G, Scholz IM, Weiss J. 2011. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics. 12(6):861–872. doi:10.2217/pgs.11.18.
   PubMed Web of Science ®Google Scholar
• Mousavi B, Hedayati MT, Hedayati N, Ilkit M, Syedmousavi S. 2016. Aspergillus species in indoor environments and their possible occupational and public health hazards. Curr Med Mycol. 2(1):36–42. doi:10.18869/acadpub.cmm.2.1.36.
   PubMedGoogle Scholar
• Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 46(2):201–211. doi:10.1086/524669.
   PubMed Web of Science ®Google Scholar
• Pawar P, Kashyap H, Malhotra S, Sindhu R. 2013. Hp-β-CD-voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment. Biomed Res Int. 2013:341218–341219. doi:10.1155/2013/341218.
   PubMed Web of Science ®Google Scholar
• Peyton LR, Gallagher S, Hashemzadeh M. 2015. Triazole antifungals: a review. Drugs Today (Barc). 51(12):705–718. doi:10.1358/dot.2015.51.12.2421058.
   PubMed Web of Science ®Google Scholar
• Phillips A, Fiorello CV, Baden RM, Liu JH, Burmas NC, Ruvalcaba CA, Monroy R, Mohr FC, Gehring R, Delplanque JP, et al. 2018. Amphotericin B concentrations in healthy mallard ducks (Anas platyrhynchos) following a single intratracheal dose of liposomal amphotericin B using an atomizer. Med Mycol. 56(3):322–331. doi:10.1093/mmy/myx049.
   PubMed Web of Science ®Google Scholar
• Prochownik W, Kharel MK. 2023. Ciprofloxacin. In Reference Module in Biomedical Sciences. New York: Elsevier. doi:10.1016/B978-0-12-824315-2.00366-3.
   Google Scholar
• Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. 2003a. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 56 Suppl 1(Suppl 1):17–23. doi:10.1046/j.1365-2125.2003.01994.x.
   PubMedGoogle Scholar
• Purkins L, Wood N, Kleinermans D, Nichols D. 2003b. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 56 Suppl 1(Suppl 1):51–55. doi:10.1046/j.1365-2125.2003.01999.x.
   PubMedGoogle Scholar
• Regmi NL, Abd El-Aty AM, Kuroha M, Nakamura M, Shimoda M. 2005. Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs. J Vet Pharmacol Ther. 28(6):553–557. doi:10.1111/j.1365-2885.2005.00698.x.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. 2008. Drug-drug interactions, Second Edition. Boca Raton, FL: CRC Press. Pages 277, p. 294. doi:10.1201/9780429131967.
   Google Scholar
• Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, Smith DA, Walker DK, Wood N. 2003. The disposition of voriconazole in the mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 31(6):731–741. doi:10.1124/dmd.31.6.731.
   PubMed Web of Science ®Google Scholar
• Rosenblum C. 1957. Principles of isotope dilution assays. Anal Chem. 29(12):1740–1744. doi:10.1021/ac60132a021.
   Web of Science ®Google Scholar
• Sandherr M, Maschmeyer G. 2011. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature. Eur J Med Res. 16(4):139–144. doi:10.1186/2047-783X-16-4-139.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Shimoda M. 2015. Possible drug-drug interaction in dogs and cats resulted from alteration in drug metabolism: a mini review. J Adv Res. 6(3):383–392. doi:10.1016/j.jare.2015.02.003.
   PubMed Web of Science ®Google Scholar
• Savelieff MG, Pappalardo L, Azmanis P. 2018. The current status of avian aspergillosis diagnoses: veterinary practice to novel research avenues. Vet Clin Pathol. 47(3):342–362. doi:10.1111/vcp.12644.
   PubMed Web of Science ®Google Scholar
• Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C. 2019. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 51(3):247–265. doi:10.1080/03602532.2019.1632888.
   PubMed Web of Science ®Google Scholar
• Schwinghammer TL. 1981. Drug interactions with cimetidine. Am J Hosp Pharm. 38(12):1976–1978. PMID: 7325185. doi:10.1093/ajhp/38.12.1976.
   PubMedGoogle Scholar
• Shafiei M, Peyton L, Hashemzadeh M, Foroumadi A. 2020. History of the development of antifungal azoles: a review on structures, SAR, and mechanism of action. Bioorg Chem. 104:104240. doi:10.1016/j.bioorg.2020.104240.
   PubMed Web of Science ®Google Scholar
• Shamburek RD, Schubert ML. 1992. Control of gastric acid secretion. Histamine H2-receptor antagonists and H + K(+)-ATPase inhibitors. Gastroenterol Clin North Am. 21(3):527–550. PMID: 1355465. doi:10.1016/S0889-8553(21)00047-9.
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. 2013. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos. 41(7):1414–1424. doi:10.1124/dmd.113.051722.
   PubMed Web of Science ®Google Scholar
• Smith A, Leung-Pineda V. 2016. Determination of voriconazole concentrations in serum by GC-MS. J Clin Lab Anal. 30(5):411–417. doi:10.1002/jcla.21871.
   PubMed Web of Science ®Google Scholar
• Sumonrat C, Jantararoungtong T, Chitasombat MN, Puangpetch A, Prommas S, Dilokpattanamongkol P, Watcharananan SP, Sukasem C. 2016. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. Drug Metab Pharmacokinet. 31(2):117–122. doi:10.1016/j.dmpk.2015.12.005.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. 2006. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 45(7):649–663. doi:10.2165/00003088-200645070-00002.
   PubMed Web of Science ®Google Scholar
• Toyotome T, Matsumoto N, Itoh M, Yamada K. 2022. Countermeasures against aspergillosis in captive penguins. Med Mycol J. 63(2):49–52. doi:10.3314/mmj.22.002.
   PubMed Web of Science ®Google Scholar
• Uptodate.com. 2023. Cytochrome P450 3A (including 3A4) inhibitors and inducers. Available at https://www.uptodate.com/contents/image?imageKey=CARD/76992., accessed August 24, 2023.
   Google Scholar
• Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Verhoeven H, Coene MC, Lauwers W, Janssen PA. 1987. Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells. Pestic Sci. 21(4):289–306. doi:10.1002/ps.2780210406.
   Google Scholar
• Wagenlehner FME, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG. 2006. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents. 28(6):551–559. doi:10.1016/j.ijantimicag.2006.07.026.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhou S-F. 2009. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 16(31):4066–4218. doi:10.2174/092986709789378198.
   PubMed Web of Science ®Google Scholar
• Ward NE, Jones JE, Maurice DV. 1987. Research note: ability of cimetidine to increase intestinal pH of chicks. Poult Sci. 66(5):910–912. doi:10.3382/ps.0660910.
   PubMed Web of Science ®Google Scholar
• Warrilow AGS, Parker JE, Price CL, Rolley NJ, Nes WD, Kelly DE, Kelly SL. 2019. Isavuconazole and voriconazole inhibition of sterol 14 α-demethylases (CYP51) from Aspergillus fumigatus and Homo sapiens. Int J Antimicrob Agents. 54(4):449–455. doi:10.1016/j.ijantimicag.2019.07.011.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Pennick GJ, Dorsey SA, Furmaga W, Lewis JS, 2nd, Patterson TF, Sutton DA, Fothergill AW. 2014. A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother. 58(1):424–431. doi:10.1128/AAC.01558-13.
   PubMed Web of Science ®Google Scholar
• Yi WM, Schoeppler KE, Jaeger J, Mueller SW, MacLaren R, Fish DN, Kiser TH. 2017. Voriconazole and Posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 16(1):60. doi:10.1186/s12941-017-0235-8.
   PubMedGoogle Scholar
• Zhang J, Li L, Lv Q, Yan L, Yan W, Jiang Y. 2019. The fungal CYP51s: their functions, structures, related drug resistance, and inhibitors. Front Microbiol. 10:691. doi:10.3389/fmicb.2019.00691.
   PubMed Web of Science ®Google Scholar
• Zhou L, Glickman RD, Chen N, Sponsel WE, Graybill JR, Lam KW. 2002. Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 776(2):213–220. doi:10.1016/s1570-0232(02)00344-6.
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. 1994. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 46(2):147–150. doi:10.1007/BF00199879.
   PubMed Web of Science ®Google Scholar